CIRculating CANcer MAster-Protocol

NCT05089747 | Recruiting

• 1 other identifier: 69HCL21_0918
• Study Type: observational
• Target: 6,000
• Locations: 1 country
• Sites: 7

Brief Summary

This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease

Conditions

Adult With Solid Cancer

Keywords

liquid biopsy; solid cancer

Outcome Measures

Primary Outcomes (3)

• Liquid biopsy analyses

  Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.

  Day 0

• Standard technics of disease assessment

  Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.

  Week 16

• Correlation between outcome 1 and outcome 2

  Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.

  year 5

Study Arms (1)

Adult with solid cancer. No intervention.

Biological: Blood sampling for biomarker analysis (microRNA, circulating DNA…)

Interventions

Blood sampling for biomarker analysis (microRNA, circulating DNA…) BIOLOGICAL

From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).

Adult with solid cancer. No intervention.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult with solid cancer

You may qualify if:

• Adult (\>18y)
• Owing a social security insurance
• Any solid cancer diagnosed by histopathology or cytology
• Patient with blood sampling required as per standard of care
• Informed consent signed

You may not qualify if:

• Refusal to participate
• No blood sampling required as per standard of care
• Hemoglobin \< 7g/dl (\< 9g/dl if respiratory or cardiovascular disease history)
• Heterologous blood transfusion in the last 48 hours
• Weight under 20 kg

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (7)

Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est

Bron, 69500, France

RECRUITING

Hôpital Edouard Herriot / Groupement Hospitalier Centre

Lyon, 69003, France

RECRUITING

Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord

Lyon, 69004, France

RECRUITING

Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Groupement Hospitalier Sud

Pierre-Bénite, 69310, France

RECRUITING

Hôpital Lyon-Sud / Groupement Hospitalier Sud

Pierre-Bénite, 69495, France

RECRUITING

Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud

Pierre-Bénite, 69495, France

RECRUITING

Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud

Pierre-Bénite, 69495, France

RECRUITING

MeSH Terms

Interventions

Blood Specimen Collection; MicroRNAs; Cell-Free Nucleic Acids

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; RNA, Antisense; Antisense Elements (Genetics); Nucleic Acids, Nucleotides, and Nucleosides; RNA; Nucleic Acids; RNA, Small Untranslated; RNA, Untranslated

Central Study Contacts

Sebastian Couraud, MD, PhD

CONTACT

+33 4 478 864 401; sebastien.couraud@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 11, 2021
• First Posted: October 22, 2021
• Study Start: December 5, 2022
• Primary Completion (Estimated): December 1, 2047
• Study Completion (Estimated): December 1, 2047
• Last Updated: June 10, 2026

Record last verified: 2026-06

Locations

FR (7)